.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EH02_Neratinib.Neratinib

Information

name:Neratinib
ATC code:L01EH02
route:oral
n-compartments2

Neratinib is an oral, irreversible tyrosine kinase inhibitor targeting HER2 and EGFR receptors. It is primarily used for the extended adjuvant treatment of early-stage HER2-positive breast cancer and is an FDA-approved medication.

Pharmacokinetics

Population pharmacokinetics in cancer patients (mainly women, adults) after oral administration; parameters represent typical values from published clinical pharmacology studies.

References

    Revisions

    Generated at 2025-07-21T18:21:10Z by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos